Table 2.
Comparison of examination, diagnosis, and treatment between two groups
| Data | NNO group (n=85) | ANO group (n=61) | t/χ2 | P |
|---|---|---|---|---|
| Neonatal cerebral ultrasound findings | ||||
| Hemorrhagic lesions [n (%)] | 12 (14.12%) | 20 (32.79%) | 7.233 | 0.007 |
| Ischemic lesions [n (%)] | 15 (17.65%) | 25 (40.98%) | 9.723 | 0.002 |
| Other lesions [n (%)] | 19 (22.35%) | 12 (19.67%) | 0.153 | 0.696 |
| Complications during hospitalization | ||||
| NRDS [n (%)] | 42 (49.41%) | 33 (54.1%) | 0.312 | 0.576 |
| BPD [n (%)] | 41 (48.24%) | 44 (72.13%) | 8.337 | 0.004 |
| PDA [n (%)] | 18 (21.18%) | 15 (24.59%) | 0.237 | 0.627 |
| NEC [n (%)] | 5 (5.88%) | 5 (8.2%) | 0.046 | 0.831 |
| ROP [n (%)] | 38 (44.71%) | 30 (49.18%) | 0.286 | 0.593 |
| Hypoglycemia [n (%)] | 15 (17.65%) | 12 (19.67%) | 0.097 | 0.756 |
| Sepsis [n (%)] | 24 (28.24%) | 18 (29.51%) | 0.028 | 0.867 |
| Treatment measures | ||||
| Duration of Mechanical Ventilation (days) | 14.51 ± 4.37 | 17.08 ± 6.53 | 2.677 | 0.009 |
| Duration of Oxygen Therapy (days) | 45.71 ± 14.89 | 53.28 ± 17.37 | 2.826 | 0.005 |
| Use of Ibuprofen [n (%)] | 8 (9.41%) | 2 (3.28%) | 1.243 | 0.265 |
NNO: Normal Neurodevelopmental Outcome; ANO: Adverse Neurodevelopmental Outcome; NRDS: Neonatal Respiratory Distress Syndrome; BPD: Bronchopulmonary Dysplasia; PDA: Patent Ductus Arteriosus; NEC: Necrotizing Enterocolitis; ROP: Retinopathy of Prematurity.